.png "PTC Therapeutics (NASDAQ: PTCT)")
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PTC Therapeutics (NASDAQ: PTCT) and CytomX Therapeutics Inc (NASDAQ: CTMX).
PTC Therapeutics (NASDAQ: PTCT)
In a report released yesterday, Raju Prasad from William Blair maintained a Hold rating on PTC Therapeutics (NASDAQ: PTCT). The company’s shares closed yesterday at $30.74, close to its 52-week high of $33.22.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 25.0% and a 61.1% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Audentes Therapeutics, and Spark Therapeutics.
Currently, the analyst consensus on PTC Therapeutics is Hold and the average price target is $30, representing a -2.4% downside.
In a report issued on May 2, Cowen & Co. also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
CytomX Therapeutics Inc (NASDAQ: CTMX)
Cantor Fitzgerald analyst Mara Goldstein maintained a Buy rating on CytomX Therapeutics Inc (NASDAQ: CTMX) yesterday and set a price target of $40. The company’s shares closed yesterday at $24.40.
Goldstein wrote:
“CX-072 Data at ASCO. CTMX’s lead proprietary program, CX-072, will have first in human data at ASCO, both monotherapy (“A”) arm and combination with ipilimumab (“B”) arm. Since these data are early and not complete data sets, high levels of response rates may not be likely, but we think activity, even a modest level, could represent upside for the shares given that this is first in human data. We think a key proof of the technology will be measurement of systemically active versus “intact” Probody CX-072.”
According to TipRanks.com, Goldstein is ranked 0 out of 5 stars with an average return of -2.2% and a 36.9% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Karyopharm Therapeutics, and Cascadian Therapeutics.
CytomX Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
